Abstract
We present a case of primary hepatic and possible splenic invasive aspergillosis (IA), which progressed under anti-CD20 B cell treatment for posttransplantation lymphoproliferative disease following allogeneic stem cell transplantation, to highlight the clinical value of a positive galactomannan-antigen test, an intestinal portal of entry of Aspergillus, and the detrimental effect of B lymphocyte depletion in IA.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Murine-Derived
-
Antifungal Agents / administration & dosage
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Aspergillosis / blood
-
Aspergillosis / chemically induced*
-
Aspergillosis / drug therapy
-
Chemical and Drug Induced Liver Injury*
-
Fatal Outcome
-
Female
-
Galactose / analogs & derivatives
-
Graft vs Host Disease / blood
-
Graft vs Host Disease / drug therapy
-
Graft vs Host Disease / etiology
-
Humans
-
Liver Diseases / blood
-
Liver Diseases / drug therapy
-
Lymphoproliferative Disorders / blood
-
Lymphoproliferative Disorders / complications*
-
Lymphoproliferative Disorders / diagnosis
-
Lymphoproliferative Disorders / therapy
-
Mannans / blood
-
Middle Aged
-
Pyrimidines / administration & dosage
-
Rituximab
-
Splenic Diseases / blood
-
Splenic Diseases / chemically induced*
-
Splenic Diseases / drug therapy
-
Stem Cell Transplantation / adverse effects
-
Transplantation, Homologous
-
Triazoles / administration & dosage
-
Voriconazole
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antifungal Agents
-
Antineoplastic Agents
-
Mannans
-
Pyrimidines
-
Triazoles
-
galactomannan
-
Rituximab
-
Voriconazole
-
Galactose